Alizé Pharma acquires exclusive worldwide rights on a new peptide to tackle bone diseases
3 December 2014 | By Alizé Pharma III SAS
Dr. David Clemmons, co-inventor of the technology and a highly reputable key opinion leader in endocrinology and metabolism, will collaborate on the drug optimization and development programs...